Atebimetinib

Atebimetinib
Clinical data
Other namesIMM-1-104
Identifiers
  • [4-[(dimethylamino)methyl]-3-[[2-fluoro-3-(methylsulfamoylamino)phenyl]methyl]-2-oxochromen-7-yl] N,N-dimethylcarbamate
CAS Number
PubChem CID
IUPHAR/BPS
UNII
KEGG
Chemical and physical data
FormulaC23H27FN4O6S
Molar mass506.55 g·mol−1
3D model (JSmol)
  • CNS(=O)(=O)NC1=CC=CC(=C1F)CC2=C(C3=C(C=C(C=C3)OC(=O)N(C)C)OC2=O)CN(C)C
  • InChI=InChI=1S/C23H27FN4O6S/c1-25-35(31,32)26-19-8-6-7-14(21(19)24)11-17-18(13-27(2)3)16-10-9-15(33-23(30)28(4)5)12-20(16)34-22(17)29/h6-10,12,25-26H,11,13H2,1-5H3
  • Key:VGDONWMTHHBKMZ-UHFFFAOYSA-N

Atebimetinib is an investigational new drug that is being developed by Immuneering Corporation for the treatment of pancreatic cancer. It is a dual MEK1/MEK2 inhibitor[1] of mitogen-activated protein kinase kinase.[2][3][4]

References

  1. ↑ Clinical trial number NCT05585320 for "A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors" at ClinicalTrials.gov
  2. ↑ "Atebimetinib - Immuneering". AdisInsight. Springer Nature Switzerland AG.
  3. ↑ WO 2023133472, Hall BM, Decorte BL, King PJ, Leenders R, Wegert A, Fowler K, Kolitz S, Doodeman R, Poelakker J, Folmer RH, "Mek immune oncology inhibitors and therapeutic uses thereof", published 13 July 2023, assigned to Immuneering Corp
  4. ↑ Li M, Wang X, Li P, Gong H, Wu J, Mao Y (May 2026). "Current advances in immunotherapy for KRAS-Mutant pancreatic cancer". Clinical and Experimental Medicine. doi:10.1007/s10238-026-02201-8. PMID 42218726.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.